Fundraising FoxMolecular Assemblies
San Diego, US · Delaware corporation · 9 known investors
Find your way into Molecular Assemblies
Sign up to see every warm intro you have to Molecular Assemblies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Molecular Assemblies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification. The company serves researchers and developers in therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology.
Founders & leadership
Board
Investors · 9
How we know: 11.2 Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: iSelect Fund's portfolio page · a partner's Signal profile · funding news · Not right? Tell us
How we know: Keshif Ventures's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$46.6M disclosed across 3 of 4 rounds · 2016–2021
▶$25.9MraisedSep 2022 · 14 investors · BiotechnologyRule 506(b)
- Helge BastianDirector
- John NicolsDirector
- J. William Efcavitch, Ph.D.Executive Officer, Director
- Michael J. KamdarExecutive Officer, Director
- Todd PetersonDirector
- Jeffrey Sampson, Ph.D.Director
- Larry StambaughDirector
- Offering amount
- $40M
- Amount sold
- $25.9M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.1MraisedSep 2021 · 22 investors · BiotechnologyRule 506(b)
- Michael J. KamdarExecutive Officer, Director
- David HwangDirector
- Larry StambaughDirector
- John NicolsDirector
- Todd PetersonDirector
- Helge BastianDirector
- J. William Efcavitch, Ph.D.Executive Officer, Director
- Offering amount
- $16.3M
- Amount sold
- $14.1M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MofferedJul 2020 · BiotechnologyRule 506(b)
- Michael J. KamdarDirector, Executive Officer
- David HwangDirector
- Larry StambaughDirector
- J. William Efcavitch, Ph.D.Director, Executive Officer
- John NicolsDirector
- Todd PetersonDirector
- Helge BastianDirector
- Offering amount
- $4.2M
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$6.5MraisedJul 2018 · 36 investors · BiotechnologyRule 506(b)
- Larry StambaughDirector
- J. William Efcavitch, Ph.D.Director, Executive Officer
- Joe H. SmithDirector
- Michael J. KamdarDirector, Executive Officer
- Sean FreemanExecutive Officer, Director
- Offering amount
- $9.8M
- Amount sold
- $6.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, California, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $256.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $189K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $223K |
| National Science Foundation | Phase I | 2014 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Molecular Assemblies do?
- Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification. The company serves researchers and developers in therapeutics, vaccines, immunotherapy, agriculture, and nanotechnology.
- Who founded Molecular Assemblies?
- Molecular Assemblies was founded by J. William Efcavitch, Ph.D..
- Who are Molecular Assemblies's investors?
- Molecular Assemblies's investors include 11.2 Capital, DCVC (Data Collective), iSelect Fund, Keshif Ventures, Rising Tide, Alexandria, Argonautic Ventures, Casdin Capital and 1 more.
- How much funding has Molecular Assemblies raised?
- Molecular Assemblies has disclosed $46.6M raised across 3 of its 4 known rounds.
- Where is Molecular Assemblies headquartered?
- Molecular Assemblies is headquartered in San Diego, US.